Show simple item record

dc.contributor.authorSanten, Richard J
dc.contributor.authorBoyd, Norman F
dc.contributor.authorChlebowski, Rowan T
dc.contributor.authorCummings, Steven
dc.contributor.authorCuzick, Jack
dc.contributor.authorDowsett, Mitch
dc.contributor.authorEaston, Douglas
dc.contributor.authorForbes, John F
dc.contributor.authorKey, Tim
dc.contributor.authorHankinson, Susan E
dc.contributor.authorHowell, Anthony
dc.contributor.authorIngle, James
dc.date.accessioned2009-06-12T09:27:55Z
dc.date.available2009-06-12T09:27:55Z
dc.date.issued2007-06-01
dc.identifier.citationCritical assessment of new risk factors for breast cancer: considerations for development of an improved risk prediction model. 2007, 14 (2):169-87 Endocr. Relat. Canceren
dc.identifier.issn1351-0088
dc.identifier.pmid17639036
dc.identifier.doi10.1677/ERC-06-0045
dc.identifier.urihttp://hdl.handle.net/10541/70259
dc.description.abstractThe majority of candidates for breast cancer prevention have not accepted tamoxifen because of the perception of an unfavorable risk/benefit ratio and the acceptance of raloxifene remains to be determined. One means of improving this ratio is to identify women at very high risk of breast cancer. Family history, age, atypia in a benign biopsy, and reproductive factors are the main parameters currently used to determine risk. The most powerful risk factor, mammographic density, is not presently employed routinely. Other potentially important factors are plasma estrogen and androgen levels, bone density, weight gain, age of menopause, and fracture history, which are also not currently used in a comprehensive risk prediction model because of lack of prospective validation. The Breast Cancer Prevention Collaborative Group (BCPCG) met to critically examine and prioritize risk factors that might be selected for further testing by multivariate analysis using existing clinical material. The BCPCG reached a consensus that quantitative breast density, state of the art plasma estrogen and androgen measurements, history of fracture and height loss, BMI, and waist-hip ratio had sufficient priority for further testing. As a practical approach, these parameters could be added to the existing Tyrer-Cuzick model which encompasses factors included in both the Claus and Gail models. The BCPCG analyzed potentially available clinical material from previous prospective studies and determined that a large case/control study to evaluate these new factors might be feasible at this time.
dc.language.isoenen
dc.subjectBreast Canceren
dc.subjectBreast Cancer
dc.subject.meshBone Density
dc.subject.meshBreast Neoplasms
dc.subject.meshFemale
dc.subject.meshGonadal Steroid Hormones
dc.subject.meshHumans
dc.subject.meshMenopause
dc.subject.meshModels, Biological
dc.subject.meshPrognosis
dc.subject.meshRisk Assessment
dc.subject.meshRisk Factors
dc.titleCritical assessment of new risk factors for breast cancer: considerations for development of an improved risk prediction modelen
dc.typeArticleen
dc.contributor.departmentDepartment of Internal Medicine/Endocrinology, University of Virginia Health System, Box 801416, Charlottesville, Virginia 22908, USA.en
dc.identifier.journalEndocrine-Related Canceren
html.description.abstractThe majority of candidates for breast cancer prevention have not accepted tamoxifen because of the perception of an unfavorable risk/benefit ratio and the acceptance of raloxifene remains to be determined. One means of improving this ratio is to identify women at very high risk of breast cancer. Family history, age, atypia in a benign biopsy, and reproductive factors are the main parameters currently used to determine risk. The most powerful risk factor, mammographic density, is not presently employed routinely. Other potentially important factors are plasma estrogen and androgen levels, bone density, weight gain, age of menopause, and fracture history, which are also not currently used in a comprehensive risk prediction model because of lack of prospective validation. The Breast Cancer Prevention Collaborative Group (BCPCG) met to critically examine and prioritize risk factors that might be selected for further testing by multivariate analysis using existing clinical material. The BCPCG reached a consensus that quantitative breast density, state of the art plasma estrogen and androgen measurements, history of fracture and height loss, BMI, and waist-hip ratio had sufficient priority for further testing. As a practical approach, these parameters could be added to the existing Tyrer-Cuzick model which encompasses factors included in both the Claus and Gail models. The BCPCG analyzed potentially available clinical material from previous prospective studies and determined that a large case/control study to evaluate these new factors might be feasible at this time.


This item appears in the following Collection(s)

Show simple item record